CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) clinical trials

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

This study is looking at a new treatment called CSL222 for teenage boys with severe or moderately severe haemophilia B. It's a single injection aimed at improving how their blood clots and reducing bleeding episodes. Researchers want to check if it's safe and effective.